5450012026-07-012026-09-305450012026-09-305450012026-03-315450012026-04-012026-09-305450012026-07-012026-09-30in-capmkt:OtherExpenses1Member5450012026-04-012026-09-30in-capmkt:OtherExpenses1Member5450012026-09-30OtherNoncurrentFinancialAssetsDomain15450012026-09-30OtherNoncurrentFinancialAssetsDomain25450012026-09-30OtherNoncurrentFinancialAssetsDomain35450012026-09-30OtherNoncurrentFinancialAssetsDomain45450012026-09-30OtherNoncurrentAssetsDomain15450012026-09-30OtherNoncurrentAssetsDomain25450012026-09-30OtherNoncurrentAssetsDomain35450012026-09-30OtherNoncurrentAssetsDomain45450012026-09-30OtherCurrentFinancialAssetsDomain15450012026-09-30OtherCurrentFinancialAssetsDomain25450012026-09-30OtherCurrentFinancialAssetsDomain35450012026-09-30OtherCurrentFinancialAssetsDomain45450012026-09-30OtherCurrentFinancialAssetsDomain55450012026-09-30OtherCurrentAssetsDomain15450012026-09-30OtherCurrentAssetsDomain25450012026-09-30OtherCurrentAssetsDomain35450012026-09-30OtherCurrentAssetsDomain45450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain15450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain25450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain35450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain45450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain55450012026-09-30OtherNoncurrentFinancialLiabilitiesDomain65450012026-09-30OtherCurrentFinancialLiabilitiesDomain15450012026-09-30OtherCurrentFinancialLiabilitiesDomain25450012026-09-30OtherCurrentFinancialLiabilitiesDomain35450012026-09-30OtherCurrentFinancialLiabilitiesDomain45450012026-09-30OtherCurrentFinancialLiabilitiesDomain55450012026-09-30OtherCurrentFinancialLiabilitiesDomain65450012026-09-30OtherCurrentLiabilitiesDomain15450012026-09-30OtherCurrentLiabilitiesDomain25450012026-09-30OtherCurrentLiabilitiesDomain35450012026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15450012026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15450012026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15450012026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25450012026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15450012026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares545001SMTNOTLISTEDINE356Y01018Sahajanand Medical Technologies LimitedMain BoardEquity2026-04-012027-03-312026-11-052026-10-26INRLakhsQuarterlySecond quarterSingle segmentCardiovascular Devices2026-11-0515:00:002026-11-0516:43:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated3734101000223580003756459000799542000336822000-18024800010127470006811800020909100011097000003355772000400687000040068700012886400071310001359950000264692000000026469200017108000281800000257906000678600027455800072420009813100012.632.56002.632.56Explanatory Notes to the Unaudited Consolidated Financial Results: <br /> <br /> 1. The Unaudited Consolidated Financial Results for the quarter and six month ended 30 September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 November, 2026 and a limited review of the same has been carried out by the Statutory Auditors of the Company. <br /> <br /> 2. The Parent Company's equity shares have been listed on Bombay Stock Exchange Limited ("BSE") and on National Stock Exchange of India Limited ("NSE") on 23 October 2026 by completing Initial Public Offering of 1,38,22,116 equity shares of face value of Re. 1 each and issue price of Rs. 344 per equity share, consisting of an offer for sale by selling shareholders. Accordingly, the above Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026 ("the Statement") are drawn up in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ("Listing Requirements") as amended. <br /> <br /> 3. The Unaudited Consolidated Financial Results of Sahajanand Medical Technologies Limited  ("the Parent"/ “Company”) and its Subsidiaries (the parent and its subsidiaries together referred to as "the Group") comprises the Consolidated Statement of Profit and Loss (including Other Comprehensive Income) for the quarter and six month ended 30 September, 2026 and Explanatory Notes (together referred to as the “Unaudited Consolidated Financial Results”). <br /> <br /> The Unaudited Consolidated Financial Results have been prepared in accordance with the recognition and measurement principle of Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”) prescribed under Section 133 of the Companies Act, 2013 (the “Act”), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> <br /> 4. The Group is engaged in the business of manufacturing Balloon Catheter, Cardiac Stents, TAVI and Occluder and the Company's Chief Operating Decision Maker (CODM) evaluates the Company's performance, allocates resources as a single segment "Cardiovascular Devices". Accordingly, no separate disclosure of segment has been made. <br /> <br /> 5. The Unaudited Consolidated Financial Results and notes are also available on the websites of Stock Exchange via www.bseindia.com and www.nseindia.com and also on the website of the Parent Company at www.smtpl.com.2026-04-012026-09-30UnauditedConsolidated72507860004900800072997940001430338000662179000-2255170001986657000133583000413218000225579700066562550006435390000643539000238419000-1049500022792400004156150000000415615000-1759300039802200040362500011990000386098000119240009813100014.114.01004.114.01Other Expenses1109700000Other Expenses225579700027751300001458880004937070001144270007598000299844000369300001482620004850360005182380001647640004704788000330269600033012800031814800007816400003163200082770002251890004558346000694875000855591700013260705000981310007274720000737285100080247000745309800065809300034418800010022810001192400024988000103919300023588980006699000096246600010294560006795570004067911000213640000206400004662230004768414000580760700013260705000Security Deposits92163000Deposits with banks with maturity of more than 12 months (refer footnote)42769000Interest Receivable on Unsecured Loans & Deposits3446000Income Tax Assets (net)9884000Indirect taxes recoverable21818000Capital Advance14006000Prepaid expenses2119000Balance with Government Authorities (paid under protest)126821000Security Deposits (Considered good)2962000Deposits with banks original maturity of more than 12 months and remaining maturity of less than 12 months (refer footnote (i) and (ii))25584000Interest Receivable on unsecured loans and deposits3390000Other receivables (Considered good)4662000Receivable from selling shareholders (Considered good) (refer footnote (iii))188591000Indirect taxes recoverable (Net of provision: Rs.4,493.13 lacs)381647000Advance to suppliers167699000Prepaid expenses131552000Advances to employees13977000Lease Liabilities180313000Security Deposits from others225000Security Deposit from Customer1623000Put option liability towards Non-controlling Interest Shareholder32384000Employee related liabilities55933000Gratuity Payable73710000Lease Liabilities120398000Capital Creditors18836000Employee related liabilities337138000Interest accrued but not due on borrowings29803000Leave Encashment Payable167933000Other Payables5449000Contract Liabilities (Refer footnote below)37749000Deferred Income47000Statutory dues175844000133583000-210424000-2481040007000000000092717000000413218000-197130000000-144277000016960000321290000000-20380000308310006743700000002007300000473640000003163000075967000000062810004213280000000000000000423000000029993000031690000-39812400001708120000000003399410001250600075920000011442400000-3372100041795000-38500041410000740930000782340000Re-measurement Income on defined benefit obligation00Re-measurement Income on defined benefit obligation-21692000-216920000-5087000Exchange Gain on translation of financial statements of foreign operations17108000Exchange loss on translation of financial statements of foreign operations017108000Exchange Gain on translation of financial statements of foreign operations0Exchange loss on translation of financial statements of foreign operations-988000-9880000017108000-17593000